TY - JOUR
T1 - Measuring quality of care for ischemic stroke treated with acute reperfusion therapy in Japan ― the close the gap-stroke ―
AU - Ren, Nice
AU - Nishimura, Ataru
AU - Kurogi, Ai
AU - Nishimura, Kunihiro
AU - Matsuo, Ryu
AU - Ogasawara, Kuniaki
AU - Hashimoto, Yoichiro
AU - Higashi, Takahiro
AU - Sakai, Nobuyuki
AU - Toyoda, Kazunori
AU - Shiokawa, Yoshiaki
AU - Tominaga, Teiji
AU - Miyachi, Shigeru
AU - Kada, Akiko
AU - Abe, Keisuke
AU - Ono, Kotaro
AU - Matsumizu, Kazunori
AU - Arimura, Koichi
AU - Kitazono, Takanari
AU - Miyamoto, Susumu
AU - Minematsu, Kazuo
AU - Iihara, Koji
N1 - Publisher Copyright:
© 2021 Japanese Circulation Society. All rights reserved.
PY - 2021/2
Y1 - 2021/2
N2 - Background: In Japan there is no consensus on how to efficiently measure quality indicators (QIs), defined as a standard of care, for acute ischemic stroke (AIS). Using information from a health insurance claims database and electronic medical records, we evaluated the feasibility and validity of measuring QIs for AIS patients who received intravenous recombinant tissue plasminogen activator (IV rt-PA) or endovascular therapy (EVT). Methods and Results: AIS patients receiving rt-PA or EVT between 2013 and 2015 were identified. We selected 17 AIS QI measures for primary stroke centers (PSCs) and 8 for comprehensive stroke centers (CSCs). Defined QIs were calculated for each hospital and then averaged. In total, the data of 8,206 patients (rt-PA 83.7%, EVT 34.9%) from 172 hospitals were obtained. Median National Institute of Health Stroke Scale score at admission was 14, and 37.7% of the patients were functionally independent at discharge. All target QIs were successfully measured with fewer missing values, and the accuracy of preset data was about 90%. Adherence rates were low (<50%) in 5 QI measures among PSCs, including door-to-needle time ≤1h, and in 1 QI measure among CSCs (door-to-brain and vascular imaging time ≤30min). Conclusions: Measuring QIs for AIS by this novel approach was feasible and reliable in the provision of a national benchmark.
AB - Background: In Japan there is no consensus on how to efficiently measure quality indicators (QIs), defined as a standard of care, for acute ischemic stroke (AIS). Using information from a health insurance claims database and electronic medical records, we evaluated the feasibility and validity of measuring QIs for AIS patients who received intravenous recombinant tissue plasminogen activator (IV rt-PA) or endovascular therapy (EVT). Methods and Results: AIS patients receiving rt-PA or EVT between 2013 and 2015 were identified. We selected 17 AIS QI measures for primary stroke centers (PSCs) and 8 for comprehensive stroke centers (CSCs). Defined QIs were calculated for each hospital and then averaged. In total, the data of 8,206 patients (rt-PA 83.7%, EVT 34.9%) from 172 hospitals were obtained. Median National Institute of Health Stroke Scale score at admission was 14, and 37.7% of the patients were functionally independent at discharge. All target QIs were successfully measured with fewer missing values, and the accuracy of preset data was about 90%. Adherence rates were low (<50%) in 5 QI measures among PSCs, including door-to-needle time ≤1h, and in 1 QI measure among CSCs (door-to-brain and vascular imaging time ≤30min). Conclusions: Measuring QIs for AIS by this novel approach was feasible and reliable in the provision of a national benchmark.
UR - http://www.scopus.com/inward/record.url?scp=85100357654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100357654&partnerID=8YFLogxK
U2 - 10.1253/CIRCJ.CJ-20-0639
DO - 10.1253/CIRCJ.CJ-20-0639
M3 - Article
C2 - 33229795
AN - SCOPUS:85100357654
SN - 1346-9843
VL - 85
SP - 201
EP - 209
JO - Circulation Journal
JF - Circulation Journal
IS - 2
ER -